What this trial studies
The purpose of this study is to integrate Traditional Chinese Medicine (TCM) theory and therapeutic methods with modern low-level laser stimulation on corresponding acupoints, applying this combined approach to the field of weight management in menopausal women. The trial aims to investigate whether lifestyle modifications in accordance with WHO guidelines (dietary control and exercise), combined with adjunctive low-level laser acupuncture, can enhance weight reduction and improve body composition more effectively than standard lifestyle interventions alone.
Conditions in scope
- Menopause
- Perimenopause
- Obesity
- Overweight
Interventions
- Multi-acupoint low-level laser therapy (Device) — Low-level laser therapy, 780 nm wavelength, 30 minutes per session, 12 sessions over 6 weeks, targeting 10 acupoints: bilateral Shenshu (BL23), Sanyinjiao (SP6), Tianshu (ST25), Shuifen (CV9), Guanyuan (CV4), and Dàdài (GB26).
- Sham Laser irradiation (Device) — Sham laser treatment that mimics the appearance and procedure of active low-level laser therapy but does not emit therapeutic laser energy. Sessions are conducted twice weekly for 6 weeks (12 sessions total).
- Diet and exercise guidance (Behavioral) — WHO guideline-based diet and exercise counseling; weekly 5-10 minute sessions including waist, hip, and body composition monitoring.
Who can join
Women only · Ages 45 Years to 55 Years · Accepts healthy volunteers.
Inclusion criteria
- Female participants aged 45 to 55 years
- No cognitive impairment or major psychiatric disorder
- Able to understand the study procedures and communicate with research staff
- Body mass index (BMI) \> 24 kg/m² OR waist-to-hip ratio \> 0.88
Exclusion criteria
- Pregnant or possibly pregnant women
- Diagnosed chronic diseases currently under active treatment, including hepatitis, chronic kidney disease, chronic gastrointestinal disease, cardiovascular disease, or cancer
- Systemic diseases such as hyperthyroidism, hypothyroidism, compensated liver cirrhosis, or autoimmune disorders
- Currently receiving weight control treatment, including bariatric surgery or weight-loss medications
- History of epilepsy or seizure disorder
- Coagulation disorders or current use of anticoagulant therapy
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Keelung | Taiwan | Chang Gung Memorial Hospital, Keelung Medical Center | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2026-03-16
- Primary completion: 2029-01-24
- Last update posted: 2026-03-20
- First posted: 2026-03-16
Sponsor & contact
Lead sponsor: Chang Gung Memorial Hospital (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Change in body fat mass (Baseline, Week 3, Week 4, and Week 6)
Body fat mass (kg) measured using bioelectrical impedance analysis (InBody body composition analyzer). Measurements will be performed by trained research staff.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07472881 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.